895 related articles for article (PubMed ID: 6546770)
1. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
2. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
3. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
4. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
5. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
6. Cholinergic innervation and topographical organization of muscarinic binding sites in rat brain: a comparative autoradiographic study.
Tonnaer JA; Ernste BH; Wester J; Kelder K
J Chem Neuroanat; 1988; 1(2):95-110. PubMed ID: 3267343
[TBL] [Abstract][Full Text] [Related]
7. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
8. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
9. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
10. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
Lee W; Wolfe BB
Mol Pharmacol; 1989 Nov; 36(5):749-57. PubMed ID: 2555673
[TBL] [Abstract][Full Text] [Related]
11. Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex.
Adem A; Sabbagh M; Nordberg A
J Neural Transm; 1988; 72(1):11-8. PubMed ID: 3379385
[TBL] [Abstract][Full Text] [Related]
12. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
Luthin GR; Harkness J; Artymyshyn RP; Wolfe BB
Mol Pharmacol; 1988 Sep; 34(3):327-33. PubMed ID: 3419425
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
[TBL] [Abstract][Full Text] [Related]
15. The differential loss of [3H]pirenzepine vs [3H] (-) quinuclidinylbenzilate binding to soluble rat brain muscarinic receptors indicates that pirenzepine binds to an allosteric state of the muscarinic receptor.
Roeske WR; Venter JC
Biochem Biophys Res Commun; 1984 Feb; 118(3):950-7. PubMed ID: 6546685
[TBL] [Abstract][Full Text] [Related]
16. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.
Norman AB; Eubanks JH; Creese I
J Pharmacol Exp Ther; 1989 Mar; 248(3):1116-22. PubMed ID: 2703964
[TBL] [Abstract][Full Text] [Related]
17. Differential interactions of muscarinic drugs with binding sites of [3H]pirenzepine and [3H]quinuclidinyl benzilate in rat brain tissue.
Tonnaer JA; van Vugt MA; de Boer T; de Graaf JS
Life Sci; 1987 May; 40(20):1981-7. PubMed ID: 3573989
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates.
Lee JH; el-Fakahany EE
J Pharmacol Exp Ther; 1985 Jun; 233(3):707-14. PubMed ID: 3839264
[TBL] [Abstract][Full Text] [Related]
19. Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain.
Katayama S; Ishizaki F; Yamamura Y; Khoriyama T; Kito S
Res Commun Chem Pathol Pharmacol; 1990 Sep; 69(3):261-70. PubMed ID: 2236897
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic antagonist binding site heterogeneity as evidenced by autoradiography after direct labeling with [3H]-QNB and [3H]-pirenzepine.
Wamsley JK; Gehlert DR; Roeske WR; Yamamura HI
Life Sci; 1984 Apr; 34(14):1395-402. PubMed ID: 6546776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]